The CDC Hemophilia B mutation project mutation list: a new online resource
Authors:
Open Access
- 19 August 2013
- journal article
- research article
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 1 (4) , 238-245
Abstract
Hemophilia B (HB) is caused by mutations in the human gene F9. The mutation type plays a pivotal role in genetic counseling and prediction of inhibitor development. To help the HB community understand the molecular etiology of HB, we have developed a listing of all F9 mutations that are reported to cause HB based on the literature and existing databases. The Centers for Disease Control and Prevention (CDC) Hemophilia B Mutation Project (CHBMP) mutation list is compiled in an easily accessible format of Microsoft Excel and contains 1083 unique mutations that are reported to cause HB. Each mutation is identified using Human Genome Variation Society (HGVS) nomenclature standards. The mutation types and the predicted changes in amino acids, if applicable, are also provided. Related information including the location of mutation, severity of HB, the presence of inhibitor, and original publication reference are listed as well. Therefore, our mutation list provides an easily accessible resource for genetic counselors and HB researchers to predict inhibitors. The CHBMP mutation list is freely accessible at http://www.cdc.gov/hemophiliamutations.Keywords
Funding Information
- CDC Foundation
- Pfizer Inc
This publication has 19 references indexed in Scilit:
- Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia BThrombosis and Haemostasis, 2013
- The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online ResourceHuman Mutation, 2012
- F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicityHaemophilia, 2011
- Protein molecular function influences mutation rates in human genetic diseases with allelic heterogeneityBiochemical and Biophysical Research Communications, 2011
- Inhibitor development in haemophilia B: an orphan disease in need of attentionBritish Journal of Haematology, 2007
- The N-terminal Epidermal Growth Factor-like Domain in Factor IX and Factor X Represents an Important Recognition Motif for Binding to Tissue FactorJournal of Biological Chemistry, 2002
- Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position −4Cell, 1986
- Complete nucleotide sequences of the gene for human factor IX (antihemophilic factor B)Biochemistry, 1985
- Isolation and characterization of a cDNA coding for human factor IX.Proceedings of the National Academy of Sciences, 1982
- Hemophilia B LeydenNew England Journal of Medicine, 1982